ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VSTM vs SLN // EV/EBITDA & P/E VALUATION

Verastem Inc. (NASDAQ) VS. Silence Therapeutics Plc American Depository Share (NASDAQ) • 15-METRIC TALLY: VSTM 1 — SLN 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VSTM VS. SLN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VSTM SLN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 61.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -11.72% -5.06% -6.66 SLN /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% -65.00% +245.00 VSTM /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 3.36 -3.16 SLN /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.7 78.9 -17.23 SLN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.17B $1.23B -$57.7M SLN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VSTM REV SLN REV VSTM GROSS % SLN GROSS % VSTM FCF SLN FCF
FY 2025 $30.9M $559.0K — 61.5% -$137.5M -$62.3M
FY 2024 $10.0M $43.3M — 72.7% -$104.8M -$67.9M
FY 2023 $0 $31.6M — — -$86.5M -$49.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VSTM // BETA —
SLN // BETA —